Llwytho...
Beyond chemotherapy - emerging biomarkers and therapies as SCLC enters the immune checkpoint era
For decades, clinicians have seen no therapeutic advances for SCLC, including no FDA-approved targeted therapies; recently, immune checkpoint blockade has emerged as a promising new option for the treatment of relapsed SCLC (including recent FDA approval of nivolumab in the third-line setting) and m...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Cancer |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6353664/ https://ncbi.nlm.nih.gov/pubmed/30620399 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31863 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|